Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. Their lead product candidate, Tildacerfont, has the potential to be the first FDA-approved therapy for congenital adrenal hyperplasia (CAH), a rare endocrine disease where patients are unable to make normal levels of steroid in their body. The company is currently conducting Ph II clinical trials. Spruce went public in October 2020, listing on Nasdaq with the ticker: SPRB

LocationSan Francisco, CA
CEORichard King
Partner Bali Muralidhar
Websitewww.sprucebiosciences.com